NPS PhIII data bolsters hypoparathyroidism drug
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals says that data from the double-blind, placebo-controlled Phase III REPLACE study of Natpara (formerly NPSP558) reinforce its belief that Natpara could be the first parathyroid hormone replacement therapy for adults with hypoparathyroidism.